Overview

Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease

Status:
Completed

Trial end date:
2015-07-01

Target enrollment:
0

Participant gender:
All

Summary

Cardiovascular complications account for the highest mortality in type 2 diabetic patients, mainly due to coronary artery disease (CAD).Left ventricular hypertrophy (LVH) is widespread in type 2 diabetic patients with CAD, even in the absence of hypertension .It is a strong predictor of cardiovascular events and all-cause mortality . Sitagliptin, an inhibitor of dipeptidyl peptidase-4 (DPP-4), may regress left ventricular mass (LVM) in newly diagnosed type 2 diabetic patients with CAD .

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Wuhan General Hospital of Guangzhou Military Command

Treatments:

Acarbose
Sitagliptin Phosphate

Criteria

Inclusion Criteria:Patients had to have the levels of hemoglobin A1c (HbA1c) > 7.0 %. They
also had to have either angiographically documented coronary artery disease or a previous
history of myocardial infarction. In addition, they were also required to have an office BP
< 135/85 mm Hg and the presence of LVH on echocardiography (American Society of
Echocardiography criteria LVM index [LVMI] > 115 g/m2 for men and > 95 g/m2 for women) . -

Exclusion Criteria:Patients were excluded if they were currently prescribed glucagon-like
peptide (GLP) -1 analogues or DPP-4 inhibitors or glucosidase inhibitor or
anti-hypertensive drugs (including b-blockers), diabetes medications, estrogen supplements,
thyroxine, diuretics, hypolipidemic drugs. They were also excluded if they had renal and
liver dysfunction, heart failure, or malignancy, or were unable to give informed consent.
Patients with contraindications to cardiac magnetic resonance (CMR) (pacemakers,
claustrophobia) were also excluded, as were pregnant or lactating women. -